POSA116 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Advanced/Metastatic Breast Cancer, Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative in Colombia
Abstract
Authors
M Díaz-Ortega O Gamboa D Herrera D Barbosa E Montenegro